Large cohort observational study integrates current knowledge on changes in outcome for melanoma brain metastases in tyrosine kinase inhibitor (TKI)-immunotherapy era

There has been a drastic change in the therapeutic strategy for patients with metastatic melanoma over last 7 years. Since 2011, the US Food and Drug Administration (FDA) has approved a number of drugs for advanced disease, including multi-drug combinations.